Recent groundbreaking investigations at Memorial Sloan Kettering Cancer Center (MSK) have unveiled pivotal insights into cancer biology and developmental science, shedding light on mechanisms behind acute myeloid leukemia persistence, brain morphogenesis, and the complex relationship between midlife health conditions and cancer risk. These findings not only deepen the scientific understanding of disease progression but also have significant implications for future therapeutic strategies and public health. Moreover, MSK’s clinical research has played a crucial role in the recent FDA full approval of larotrectinib, a targeted therapy for cancers with NTRK gene fusions.
At the forefront of cancer biology, MSK scientists have identified an elusive quiescent stem cell population that underlies the persistence and therapeutic resistance of acute myeloid leukemia (AML), a hematologic malignancy affecting both pediatric and adult populations. These leukemia stem cells (LSCs) evade conventional diagnostic markers and remain insulated from current treatment regimens, elucidating why AML frequently relapses despite initial remission. The rarity and dormancy of these cells pose significant challenges to both detection and eradication, underscoring the necessity for novel molecular targets.
Through meticulous single-cell analyses and molecular profiling, the research team, led by Dr. Alex Kentsis and first-author Dr. Sumiko Takao, has discovered critical regulators of these quiescent LSCs. Notably, the transcription factor JUN emerges as a key player maintaining stem cell dormancy and contributing to drug resistance across diverse AML patient samples. JUN’s regulatory role signifies a paradigm shift, revealing that interrupting quiescence pathways could sensitize LSCs to therapy. This work dovetails with burgeoning research into MYB, another transcription factor under active drug development, suggesting a future therapeutic landscape targeting stem cell quiescence to prevent relapse.
Dr. Kentsis emphasizes that overcoming quiescence-induced resistance is a fundamental hurdle in AML treatment, and targeting these molecular pathways could dramatically enhance patient outcomes. This research represents a critical advance, provoking a reevaluation of therapeutic designs that traditionally neglect the dormant cancer stem cell fraction. The detailed findings, published in Nature Communications, set a militant tone against cancer stem cell-mediated treatment failures.
Beyond oncology, MSK investigators have employed state-of-the-art single-cell RNA sequencing to decode the earliest stages of mammalian brain development. This advanced technique enables unprecedented resolution in capturing gene expression dynamics at the level of individual cells during complex morphogenetic events. The research scrutinizes the cranial neural plate’s transformation from a planar sheet into a closed neural tube, an essential process establishing the vertebrate brain’s embryonic architecture.
By constructing a high-resolution gene expression map across six progressive developmental time points in mouse embryos, the team led by Dr. Eric Brooks and senior author Dr. Jennifer Zallen provides profound insights into spatial and temporal gene regulation during neural tube formation. This map not only corroborates the activity of well-characterized developmental genes but also predicts novel candidate genes with potential roles in brain patterning, offering fertile ground for future functional studies.
Crucially, the research highlights the Sonic hedgehog signaling pathway as a fundamental orchestrator during this morphogenetic sequence. This signaling axis is vital for defining cell fates and maintaining spatial patterning along multiple embryonic axes. Collaboration with computational biologist Dr. Dana Pe’er’s lab allowed the integration of complex data analytics, reinforcing the rigor and depth of these findings. Reviews from the community hail the work as a methodical and conceptual breakthrough, advancing methodologies and providing a robust framework for developmental neurobiology. The full study is accessible in eLife, reflecting its cross-disciplinary impact.
In epidemiological realms, the MSK team has also explored how common midlife health conditions influence cancer risk. By leveraging data from nearly 130,000 adults aged 55 to 74, part of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, researchers conducted comprehensive analyses linking respiratory, cardiovascular, metabolic, and hepatic conditions with site-specific cancer incidence. The expansive nature of the cohort and longitudinal design lend significant statistical power and validity to these associations.
Among the compelling revelations is the pronounced cancer risk elevation in individuals with pre-existing liver conditions, which correlates sharply with increased liver cancer incidents. Metabolic disorders such as type 2 diabetes and obesity also demonstrate intricate relationships with cancer, elevating risks for multiple cancer types while paradoxically lowering risk for others. These nuanced connections suggest complex metabolic and inflammatory milieus modulate carcinogenesis in organ-specific and systemic fashions.
Jessica Lavery, the study’s lead epidemiologist, describes these results as potentially transformative for clinical practice, advocating for personalized cancer screening protocols tailored not only to traditional risk factors but also informed by concurrent health morbidities. This multidimensional risk stratification framework may enhance early detection and preventative oncology interventions, especially for at-risk populations.
Complementing the basic and epidemiologic research, MSK’s clinical trial infrastructure has facilitated the accelerated development and recent full FDA approval of larotrectinib (Vitrakvi®), a pioneering targeted agent inhibiting TRK fusion proteins encoded by NTRK gene rearrangements. This FDA approval, granted in April 2025, marks a significant milestone in precision oncology, acknowledging larotrectinib’s efficacy irrespective of the tumor’s tissue of origin—a paradigm of biomarker-driven therapy.
The initial accelerated FDA approval in 2018 was a landmark decision, representing a first-in-class indication grounded solely on molecular aberrations rather than histology. MSK scientists and clinicians, notably Dr. Alexander Drilon and the Early Drug Development Service, were instrumental in the rigorous clinical trials that demonstrated robust, durable responses across pediatric and adult patients with varied cancers harboring NTRK fusions.
Dr. Drilon underscores that the full regulatory endorsement affirms larotrectinib’s clinical benefit and safety profile, potentially expediting global access by informing regulatory agencies worldwide. This approval not only reflects success in targeted drug development but reinforces the viability of tumor-agnostic therapeutics tailored to genetic drivers, heralding a new era in oncology treatment.
Collectively, these diverse MSK research endeavors—from molecular oncology and developmental biology to epidemiology and clinical therapeutics—underscore a holistic strategy to unravel and combat cancer. They exemplify translational science’s power to modernize diagnostics, refine treatment paradigms, and guide public health approaches. As these insights continue to percolate through scientific and clinical communities, they promise to reshape understanding and management of cancer and developmental diseases alike, signaling hopeful horizons for patient outcomes.
Subject of Research: Molecular mechanisms underlying acute myeloid leukemia persistence and therapy resistance; gene expression dynamics in early mammalian brain development; epidemiological links between midlife health conditions and cancer risk; clinical development of targeted cancer therapeutics.
Article Title: Memorial Sloan Kettering Cancer Center Uncovers Key Regulators of Leukemia Stem Cell Quiescence, Maps Early Brain Development, Reveals Midlife Cancer Risk Factors, and Advances Targeted Therapy Approval
News Publication Date: April 2025
Web References:
Nature Communications study on AML stem cell quiescence: https://www.nature.com/articles/s41467-025-58370-9
eLife study on neural tube gene expression: https://elifesciences.org/articles/102819
JAMA Network Open study on comorbidities and cancer risk: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832233
FDA approval announcement of larotrectinib: https://www.bayer.com/en/us/news-stories/approval-of-vitrakvi
References: Detailed research articles as per above web links.
Image Credits: Memorial Sloan Kettering Cancer Center
Tags: acute myeloid leukemia persistencecancer biology advancements 2025developmental science in cancerFDA approval larotrectinibleukemia stem cells therapeutic resistancemidlife health cancer riskmolecular profiling of cancer cellsMSK cancer research breakthroughsnovel cancer treatment strategiespublic health implications of cancer researchsingle-cell analysis in oncologytargeted therapy NTRK gene fusions